Anti-tumour necrosis factor alpha biosimilar - Mabion
Latest Information Update: 22 Jun 2015
At a glance
- Originator Mabion
- Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 22 Jun 2015 Discontinued for Autoimmune disorders in Poland (unspecified route)